Cagrilintide vs Mazdutide

Cagrilintide and Mazdutide are investigational peptides under active study for metabolic disorders, but they engage different physiological pathways. Cagrilintide is a long-acting amylin analog developed by Novo Nordisk, primarily evaluated in combination with semaglutide (CagriSema) to enhance weight loss through complementary satiety signals. Mazdutide, co-developed by Innovent Biologics and Eli Lilly, is a once-weekly dual GLP-1/glucagon receptor agonist that aims to combine appetite suppression with increased energy expenditure and hepatic fat reduction. Their distinct mechanisms lead to different evidence profiles, with Cagrilintide supported by large Phase 3 trials and Mazdutide achieving regulatory approval in China. Researchers must consider these differences when designing studies targeting weight loss, glycemic control, or hepatic outcomes.

Cagrilintide is a synthetic analog of human amylin, a hormone co-secreted with insulin that activates hindbrain satiety circuits. Developed by Novo Nordisk, it is studied both as monotherapy and in fixed-dose combination with semaglutide (CagriSema). The CagriSema regimen targets complementary appetite pathways: amylin modulates brainstem signals, while GLP-1 acts on hypothalamic and gut pathways. In the REDEFINE Phase 3 program, CagriSema achieved 20.4% weight loss at 68 weeks, outperforming semaglutide alone. Novo Nordisk filed for FDA approval in 2026. Key claims include superior weight loss efficacy compared to GLP-1 monotherapy and robust standalone effects. However, the evidence base is predominantly from combination therapy, and long-term safety data remain limited.

Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist with a molecular weight of approximately 4233.7 g/mol. Co-developed by Innovent Biologics and Eli Lilly, it activates both receptors to combine GLP-1-mediated appetite suppression and glucose lowering with glucagon-induced energy expenditure and hepatic fat reduction. In June 2024, Mazdutide received approval in China for chronic weight management, making it the first dual GLP-1/glucagon agonist to achieve regulatory approval globally. Phase III trials in China are ongoing for type 2 diabetes. Key evidence includes significant weight loss in Chinese adults with obesity, effective glycemic control, and reduced hepatic fat content. The dual mechanism offers a theoretical advantage in energy expenditure, but data outside East Asian populations are sparse.

Both Cagrilintide and Mazdutide are investigated for weight management and metabolic health, including obesity and type 2 diabetes. However, their research contexts differ. Cagrilintide is primarily studied in combination with semaglutide for weight loss, with no unique standalone applications beyond metabolic disorders. Mazdutide, due to its glucagon agonism, is also explored for non-alcoholic fatty liver disease (NAFLD) and hepatic steatosis, though this is not listed as a separate application in the input. Researchers should note that while both peptides address similar endpoints, their mechanisms may produce differential effects on energy expenditure, fat distribution, and glycemic control, influencing study design and outcome measures.

Cagrilintide: In the CagriSema group, gastrointestinal adverse events occurred in 79.6% of participants versus 39.9% with placebo, including nausea, vomiting, diarrhea, and constipation. These events were generally transient and mild-to-moderate. The safety profile aligns with the GLP-1 class, with risks of pancreatitis, gallbladder events, and thyroid C-cell tumors in rodents. Mazdutide: Common GI side effects (nausea, vomiting, diarrhea) are dose-dependent and transient, consistent with GLP-1 agonists. A heart rate increase has been observed, likely a class effect. Both peptides require monitoring for GI tolerability, but Cagrilintide's higher event rate in combination therapy may necessitate dose titration. Long-term safety data for Mazdutide are limited to Chinese populations, while Cagrilintide has broader Phase 3 data.